Year |
Citation |
Score |
2024 |
Zhang KY, Parker M, Weber-Levine C, Kalluri A, Gonzalez-Gomez I, Raabe E, Dudley JC, Gocke C, Lin MT, Zou Y, Sherief M, Kamson DO, Holdhoff M, Mukherjee D, Croog V, ... Schreck KC, et al. ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors. Acta Neuropathologica. 148: 19. PMID 39141113 DOI: 10.1007/s00401-024-02785-z |
0.318 |
|
2024 |
Schaff LR, Ioannou M, Geurts M, van den Bent MJ, Mellinghoff IK, Schreck KC. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 44: e431450. PMID 38723228 DOI: 10.1200/EDBK_431450 |
0.322 |
|
2020 |
Schreck KC, Patel MP, Wemmer J, Grossman SA, Peters KB. RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. Neuro-Oncology Practice. 7: 369-375. PMID 32765888 DOI: 10.1093/Nop/Npaa006 |
0.33 |
|
2020 |
Naidoo J, Schreck KC, Hu C, Douville CB, Santa-Maria CA, Connolly RM, Holdhoff M, Lipson EJ, Parkinson R, Riemer J, Barnes A, Venkatesan A, Bettegowda C, Grossman SA, Brahmer JR. Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response. Journal of Clinical Oncology. 38: e14506-e14506. DOI: 10.1200/Jco.2020.38.15_Suppl.E14506 |
0.339 |
|
2019 |
Schreck KC, Grossman SA, Pratilas CA. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers. 11. PMID 31466300 DOI: 10.3390/Cancers11091262 |
0.417 |
|
2019 |
Ananth YV, Schreck K. CGE19-063: Creating a Clinical-Molecular Database to Study Patients with BRAF V600E-Mutated Brain Tumors Journal of the National Comprehensive Cancer Network. 17: CGE19-063. DOI: 10.6004/Jnccn.2018.7137 |
0.417 |
|
2019 |
Schreck KC, Allen A, Wang J, Pratilas CA. Abstract B074: Sapanisertib in combination with trametinib in glioblastoma models enhances target inhibition and antitumor activity Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B074 |
0.396 |
|
2018 |
Schreck KC, Grossman SA. Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System. Oncology (Williston Park, N.Y.). 32: 555-60, 569. PMID 30474103 |
0.328 |
|
2018 |
Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA. Concurrent BRAF/MEK Inhibitors in V600-Mutant High-Grade Primary Brain Tumors. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 343-347. PMID 29632053 DOI: 10.6004/Jnccn.2017.7052 |
0.445 |
|
2015 |
Brandt WD, Schreck KC, Bar EE, Taylor I, Marchionni L, Raabe E, Eberhart CG, Rodriguez FJ. Notch signaling activation in pediatric low-grade astrocytoma. Journal of Neuropathology and Experimental Neurology. 74: 121-31. PMID 25575134 DOI: 10.1097/Nen.0000000000000155 |
0.515 |
|
2015 |
Brandt WD, Schreck KC, Bar EE, Taylor I, Marchionni L, Raabe E, Eberhart CG, Rodriguez FJ. Lg-04Notch Signaling Activation In Pediatric Low-Grade Astrocytoma. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov061.73 |
0.519 |
|
2013 |
Heaphy CM, Schreck KC, Raabe E, Mao XG, An P, Chu Q, Poh W, Jiao Y, Rodriguez FJ, Odia Y, Meeker AK, Eberhart CG. A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathologica. 126: 607-8. PMID 24022427 DOI: 10.1007/S00401-013-1174-X |
0.37 |
|
2012 |
Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW, Eberhart CG. Notch signaling promotes growth and invasion in uveal melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 654-65. PMID 22228632 DOI: 10.1158/1078-0432.Ccr-11-1406 |
0.458 |
|
2011 |
Pierfelice TJ, Schreck KC, Dang L, Asnaghi L, Gaiano N, Eberhart CG. Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Research. 71: 1115-25. PMID 21245095 DOI: 10.1158/0008-5472.Can-10-0690 |
0.649 |
|
2011 |
Asnaghi L, Coonfield ML, Schreck KC, Bar EE, Handa J, Merbs S, Ebrahimi KB, Harbour JW, Eberhart CG. Abstract 1415: The Notch ligand Jag 2 promotes growth and invasion in uveal melanoma cells Cancer Research. 71: 1415-1415. DOI: 10.1158/1538-7445.Am2011-1415 |
0.399 |
|
2010 |
Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6060-70. PMID 21169257 DOI: 10.1158/1078-0432.Ccr-10-1624 |
0.733 |
|
2010 |
Silver DL, Watkins-Chow DE, Schreck KC, Pierfelice TJ, Larson DM, Burnetti AJ, Liaw HJ, Myung K, Walsh CA, Gaiano N, Pavan WJ. The exon junction complex component Magoh controls brain size by regulating neural stem cell division. Nature Neuroscience. 13: 551-8. PMID 20364144 DOI: 10.1038/Nn.2527 |
0.667 |
|
2010 |
Asnaghi L, Coonfield ML, Schreck KC, Bar EE, Handa J, Merbs S, Ebrahimi K, Harbour JW, Eberhart CG. Abstract 4141: Notch signaling: A new potential target in the treatment of uveal melanoma Cancer Research. 70: 4141-4141. DOI: 10.1158/1538-7445.Am10-4141 |
0.422 |
|
2010 |
Schreck KC, Taylor P, Bar EE, Gopalakrishnan V, Gaiano N, Eberhart CG. Abstract 14: Targeting Notch in malignant brain tumors: Crosstalk with Hedgehog as a potential mechanism of treatment resistance Cancer Research. 70: 14-14. DOI: 10.1158/1538-7445.Am10-14 |
0.748 |
|
2009 |
Schreck KC, Gaiano N. PML: a tumor suppressor essential for neocortical development. Nature Neuroscience. 12: 108-10. PMID 19172164 DOI: 10.1038/Nn0209-108 |
0.738 |
|
2008 |
Pierfelice TJ, Schreck KC, Eberhart CG, Gaiano N. Notch, neural stem cells, and brain tumors. Cold Spring Harbor Symposia On Quantitative Biology. 73: 367-75. PMID 19022772 DOI: 10.1101/Sqb.2008.73.013 |
0.695 |
|
2007 |
Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, Eberhart CG. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (Dayton, Ohio). 25: 2524-33. PMID 17628016 DOI: 10.1634/Stemcells.2007-0166 |
0.57 |
|
Show low-probability matches. |